AI Article Synopsis
- A study analyzed long-term health consequences in patients with mild COVID-19, focusing on those who were not hospitalized, observing them from April to December 2020.* -
- Out of 442 patients observed four months post-infection, around 28% showed persistent symptoms like shortness of breath, anosmia, ageusia, and fatigue, continuing on to 35% at seven months.* -
- Key findings suggest that factors such as lower initial IgG levels and specific symptoms during the acute phase (like anosmia and diarrhea) are linked to a higher risk of developing long-term symptoms, defined as post-COVID syndrome (PCS).*
Article Abstract
Background: While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients.
Methods: 958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model.
Findings: We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms.
Interpretation: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19.
Funding: COVIM:"NaFoUniMedCovid19"(FKZ: 01KX2021).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129613 | PMC |
| http://dx.doi.org/10.1016/j.lanepe.2021.100122 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
H and P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID.
Radiology
December 2024
From the Oxford Centre for Clinical Magnetic Resonance Research (OCMR), Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK (L.E.M.F., M.P.C., M.J., A.S., Z.A., S.N., D.J.T., B.R., L.V.); Oncology and Haematology Centre, Churchill Hospital, Oxford, UK (A.S.); Axcella Therapeutics, Cambridge, Mass (K.A.); and Institute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia (L.V.).
Background Emerging evidence suggests mitochondrial dysfunction may play a role in the fatigue experienced by individuals with post-COVID-19 condition (PCC), commonly called long COVID, which can be assessed using MR spectroscopy. Purpose To compare mitochondrial function between participants with fatigue-predominant PCC and healthy control participants using MR spectroscopy, and to investigate the relationship between MR spectroscopic parameters and fatigue using the 11-item Chalder fatigue questionnaire. Materials and Methods This prospective, observational, single-center study (June 2021 to January 2024) included participants with PCC who reported moderate to severe fatigue, with normal blood test and echocardiographic results, alongside control participants without fatigue symptoms.
View Article and Find Full Text PDFClinic evaluation of cognitive impairment in post-COVID syndrome: Performance on legacy pen-and-paper and new digital cognitive tests.
Brain Behav Immun Health
February 2025
Institute of Cognitive Neuroscience, University College London, London, United Kingdom.
Background: Cognitive impairment, colloquially termed "brain fog", is one of the most prevalent manifestations of post-Covid syndrome and a major contributor to impaired daily function and reduced quality of life. However, despite the high numbers of affected individuals presenting to clinical services with cognitive impairment, little work has been undertaken to date on the suitability of current memory clinic tests for identifying the cognitive deficits in this new acquired cognitive disorder.The aim of this study was therefore to determine the performance of people with post-Covid syndrome presenting with cognitive impairment on the Addenbrooke's Cognitive Examination-III (ACE-III), a cognitive test used widely in memory clinics.
View Article and Find Full Text PDFCardiovascular Complications in Children Post COVID-19: A Systematic Review.
Adv Biomed Res
October 2024
Department of Pediatrics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Cardiovascular involvements are one of the most important and threatening problems of SARS-CoV-2 infection and can cause a wide range of clinical manifestations in children. Therefore, a review of previous studies is necessary to prevent the occurrence of cardiovascular complications and reduce the risk of mortality in this age group of patients. To investigate the cardiovascular complications in children with COVID-19, international authoritative databases including PubMed, Scopus, Embase, Web of Science, Google Scholar, and Persian databases were searched using the main concepts, all articles were published between January 2020 and November 2022.
View Article and Find Full Text PDFUnderstanding Post-COVID-19: Mechanisms, Neurological Complications, Current Treatments, and Emerging Therapies.
Int J Gen Med
December 2024
Department of Health Sciences, Universidad San Francisco de Quito USFQ, School of Medicine, Quito, Ecuador.
COVID-19, a highly infectious disease, caused a worldwide pandemic in early 2020. According to the World Health Organization (WHO), COVID-19 has resulted in approximately 774 million cases and around 7 million deaths. The effects of COVID-19 are well known; however, there is a lack of information on the pathophysiological mechanisms underlying the symptoms that comprise Post-Acute COVID-19 Syndrome (PACS) or Long COVID-19.
View Article and Find Full Text PDFIncreasing number of clinically severe of Mycoplasma pneumoniae infections in children after the COVID-19 pandemic: a single centre case series.
J Pediatric Infect Dis Soc
December 2024
Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom.
In 2024, there have been increases in laboratory confirmed infections of Mycoplasma Pneumoniae infection worldwide. This case series highlights increasing frequency of Mycoplasma pneumoniae positive PCR specimens and an increased number of hospital admissions with Mycoplasma pneumoniae clinical syndromes. Within this case series, we observed, a change in the epidemiology and clinical burden of childhood Mycoplasma pneumonia disease in the post COVID-19 era.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!